KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) FCF Margin (2017 - 2025)

Alnylam Pharmaceuticals' FCF Margin history spans 17 years, with the latest figure at 14.79% for Q4 2025.

  • For Q4 2025, FCF Margin rose 3640.0% year-over-year to 14.79%; the TTM value through Dec 2025 reached 16.29%, up 1819.0%, while the annual FY2025 figure was 13.82%, 1571.0% up from the prior year.
  • FCF Margin reached 14.79% in Q4 2025 per ALNY's latest filing, down from 27.12% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 45.61% in Q3 2023 to a low of 406.55% in Q1 2025.
  • Average FCF Margin over 5 years is 48.51%, with a median of 24.7% recorded in 2023.
  • Peak YoY movement for FCF Margin: skyrocketed 11172bps in 2021, then plummeted -38960bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 66.54% in 2021, then soared by 61bps to 25.9% in 2022, then soared by 112bps to 3.03% in 2023, then plummeted by -814bps to 21.61% in 2024, then soared by 168bps to 14.79% in 2025.
  • Per Business Quant, the three most recent readings for ALNY's FCF Margin are 14.79% (Q4 2025), 27.12% (Q3 2025), and 17.33% (Q2 2025).